Top 10 Companies in the (S)-Ethyl 2‑Amino‑2‑Phenylacetate Hydrochloride (CAS 17609‑48‑2) Market (2026): Market Leaders Driving Global Demand

MARKET INSIGHTS

Global (S)-Ethyl 2‑amino‑2‑phenylacetate hydrochloride (CAS 17609‑48‑2) market size was valued at USD 28.4 million in 2025. The forecast projects a rise to USD 52.7 million by 2034, reflecting a compound annual growth rate of 7.3 % between 2026 and 2034.

(S)-Ethyl 2‑amino‑2‑phenylacetate hydrochloride is a chiral amino‑acid ester derivative that serves as a pivotal intermediate in the synthesis of optically active pharmaceuticals. Its molecular formula, C₁₀H₁₄ClNO₂, and hydrochloride salt form confer enhanced stability and ease of handling for both laboratory and industrial processes.

Demand is accelerating as the pharmaceutical and fine‑chemical sectors intensify investment in chiral chemistry, and as manufacturers across North America, Europe and Asia‑Pacific broaden their portfolios of enantiopure building blocks to satisfy evolving regulatory and therapeutic needs.

(S)-Ethyl 2‑Amino‑2‑Phenylacetate Hydrochloride (CAS 17609‑48‑2) Market – View in Detailed Research Report

Top 10 Companies

1. Hairui Chemical Co., Ltd. (China)

   Headquarters: Shanghai, China
   Key Offering: Pharmaceutical‑grade (S)-Ethyl 2‑amino‑2‑phenylacetate hydrochloride for beta‑lactam antibiotic synthesis

   Hairui’s integrated production line delivers >99 % optical purity, positioning it as a preferred supplier for large‑scale API manufacturing. The company’s recent expansion of a dedicated biocatalytic unit has cut synthesis time by 30 % and reduced solvent usage.

   Sustainability Initiatives: Investment in enzyme‑based resolution, waste‑reduction protocols and a closed‑loop solvent recovery system.

   • Biocatalytic conversion of phenylglycine to the hydrochloride salt.
   • Implementation of a 40 % energy‑saving continuous‑flow reactor.
   • Partnerships with CDMOs to supply high‑purity intermediates to global pharma.

2. Capot Chemical Co., Ltd. (China)

   Headquarters: Guangzhou, China
   Key Offering: Technical‑grade chiral intermediates for antibiotic and peptide synthesis

   Capot’s cGMP‑certified facilities cater to both domestic and export markets, offering a flexible mix of pharmaceutical and reagent grades. The firm’s recent launch of a high‑yield, low‑cost synthesis route has attracted several generic manufacturers.

   Sustainability Initiatives: Adoption of greener catalysis, reduced hazardous waste, and ISO 14001‑compliant operations.

   • Use of recyclable phase‑separating agents.
   • Implementation of real‑time impurity monitoring.
   • Collaboration with contract manufacturers for rapid scale‑up.

3. Finetech Industry Limited (China)

   Headquarters: Shenzhen, China
   Key Offering: Ultra‑high‑purity (S)-Ethyl 2‑amino‑2‑phenylacetate hydrochloride for advanced API development

   Finetech’s R&D focus on chiral resolution and impurity profiling below ICH limits has positioned it as a niche supplier for CROs and specialty pharma. Recent technology transfer initiatives have expanded its customer base in Europe.

   Sustainability Initiatives: Investment in renewable energy for production and a zero‑waste policy.

   • Solar‑powered production facility.
   • Zero‑waste solvent recycling.
   • Custom synthesis for peptide therapeutics.

4. Shanghai Trustin Chemical Co., Ltd. (China)

   Headquarters: Shanghai, China
   Key Offering: Pharmaceutical‑grade intermediates for beta‑lactam antibiotics

   Trustin’s strong compliance record and >99 % optical purity make it a trusted partner for global API manufacturers. The company’s recent investment in enzymatic resolution has lowered production costs while maintaining high purity.

   Sustainability Initiatives: Development of bio‑based catalysts and water‑less processes.

   • Enzyme‑driven chiral resolution.
   • Water‑free esterification.
   • Strategic alliances with European pharma.

5. Beijing Lunyao Tiangong Science and Technology Co., Ltd. (China)

   Headquarters: Beijing, China
   Key Offering: Technical‑grade intermediates for research laboratories

   Beijing Lunyao supplies high‑purity reagents to academic and industrial R&D. Its recent expansion of a rapid‑synthesis platform supports short‑cycle projects and reduces lead times.

   Sustainability Initiatives: Implementation of green chemistry guidelines and reduced hazardous waste.

   • Rapid‑synthesis continuous flow reactor.
   • Green solvent selection.
   • Collaboration with universities for technology transfer.

6. Hangzhou Dayangchem Co. Ltd. (China)

   Headquarters: Hangzhou, China
   Key Offering: Pharmaceutical‑grade chiral intermediates for antibiotic manufacturing

   Dayangchem’s focus on process scalability and quality control has earned it contracts with several generic manufacturers. The firm’s recent investment in a modular production line has increased throughput by 25 %.

   Sustainability Initiatives: Adoption of renewable energy sources and waste‑minimization protocols.

   • Modular production modules.
   • Renewable energy integration.
   • ISO 9001‑certified quality management.

7. Ningbo Inno Pharmchem Co., Ltd. (China)

   Headquarters: Ningbo, China
   Key Offering: Ultra‑high‑purity intermediates for specialty pharma

   Inno Pharmchem’s emphasis on stringent impurity profiling and advanced analytical methods has positioned it as a reliable partner for high‑value API production.

   Sustainability Initiatives: Implementation of a closed‑loop solvent system and energy‑efficient operations.

   • Closed‑loop solvent recovery.
   • Energy‑efficient continuous flow processes.
   • Custom synthesis for niche markets.

8. Taizhou Crene Biotechnology Co., Ltd. (China)

   Headquarters: Taizhou, China
   Key Offering: Research‑grade chiral intermediates for academic and biotech applications

   Crene’s focus on enzyme‑based resolution and rapid analytical workflows supports fast‑track R&D projects. The company’s recent collaboration with a leading university has accelerated development of novel peptide therapeutics.

   Sustainability Initiatives: Use of bio‑derived catalysts and reduced solvent consumption.

   • Bio‑derived catalytic systems.
   • Reduced solvent usage.
   • Academic partnership for drug discovery.

9. Qingdao Fengchen Technology and Trade (China)

   Headquarters: Qingdao, China
   Key Offering: Technical‑grade chiral intermediates for specialty chemistry

   Fengchen’s high‑throughput synthesis platform allows rapid scale‑up for custom orders. Its recent investment in digital process monitoring has improved yield predictability.

   Sustainability Initiatives: Implementation of smart‑factory technologies and waste‑reduction measures.

   • Digital process monitoring.
   • Smart‑factory integration.
   • Waste‑reduction protocols.

10. Amino Chemicals Ltd. (Canada)

    Headquarters: Toronto, Canada
    Key Offering: Pharmaceutical‑grade intermediates for North American markets

    Amino Chemicals’ focus on cGMP compliance and high‑purity production aligns with stringent FDA requirements. The firm’s recent expansion of a dedicated purification line has enhanced batch consistency.

    Sustainability Initiatives: Adoption of green solvents and carbon‑neutral production targets.

    • Green solvent usage.
    • Carbon‑neutral production goals.
    • Partnerships with CDMOs for rapid scale‑up.

Download FREE Sample Report

Get Full Report

Outlook

The market trajectory reflects a steady ascent toward USD 52.7 million by 2034, underpinned by a confluence of factors: expanding antibiotic pipelines, a shift toward generic production, and heightened regulatory emphasis on enantiomeric purity. Asia‑Pacific’s manufacturing advantage, combined with North America’s R&D capacity, is expected to sustain a balanced regional contribution.

Future Trends

• Continuous‑flow synthesis platforms will further reduce cycle times and energy consumption.
• Enzymatic resolution techniques are projected to dominate the next wave of chiral production, offering lower cost and higher sustainability.
• Digital twins and real‑time analytics will enable predictive quality control and rapid process optimization.
• Emerging therapeutic areas such as peptide drugs will broaden the application spectrum beyond traditional antibiotics.
• Regulatory frameworks will increasingly mandate detailed impurity profiling, incentivizing investment in advanced analytical technologies.